Abstract
Fospropofol, a phosphorylated prodrug version of the popular induction agent propofol, is hydrolyzed in vivo to release active propofol, formaldehyde, and phosphate. Pharmacodynamic studies show fospropofol provides clinically useful sedation and EEG/bispectral index suppression while causing significantly less respiratory depression than propofol. Pain at the injection site, a common complaint with propofol, was not reported with fospropofol; the major patient complaint was transitory perianal itching during the drug's administration. Although many clinicians believe fospropofol can safely be given by a registered nurse, the FDA mandated that fospropofol, like propofol, must be used only in the presence of a trained anesthesia provider.
Original language | English (US) |
---|---|
Pages (from-to) | 949-959 |
Number of pages | 11 |
Journal | Therapeutics and Clinical Risk Management |
Volume | 5 |
Issue number | 1 |
State | Published - Dec 1 2009 |
Keywords
- Fospropofol
- Monitored anesthesia care
- Propofol
ASJC Scopus subject areas
- Pharmacology (medical)
- Medicine(all)
- Pharmacology, Toxicology and Pharmaceutics(all)
- Safety Research
- Chemical Health and Safety